Karyopharm reports third quarter 2023 financial results and highlights recent company progress

– achieved third quarter 2023 total revenue of $36.0 million and u.s. xpovio® (selinexor) net product revenue of $30.2 million – –  maintains full year 2023 total revenue guidance of $145 million to $160 million, including u.s. xpovio net product revenue guidance of $110 million to $125 million – –  strong svr and tss durability observed from phase 1 study of selinexor 60mg and ruxolitinib in jak inhibitor (jaki)-naÏve myelofibrosis patients, with no svr or tss progressions observed 1  – – announced clinical trial collaboration with bristol myers squibb to evaluate novel celmod™ agent cc- 92480, mezigdomide in combination with selinexor in patients with r/r multiple myeloma progressing after t-cell immunotherapies – – conference call scheduled for today at 8:00 a.m. et – newton, mass.
KPTI Ratings Summary
KPTI Quant Ranking